Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
LOS ANGELES, June 4, 2013 (GLOBE NEWSWIRE) -- Response Genetics, Inc. (Nasdaq:RGDX), a company focused on the development and sale of molecular diagnostic tests that help determine a patient’s response to cancer therapy, today announced that it has achieved its second milestone payment in conjunction with the non-exclusive license agreement originated in 2010 with GlaxoSmithKline (“GSK”).
Help employers find you! Check out all the jobs and post your resume.